Is Orexin-B approved as a medicine, and where?

The regulatory review of Orexin-B is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.

What is Orexin-B studied for?

Orexin-B is most often discussed in the context of cognition, mood & sleep. Being studied for an area does not mean it is proven or approved for it.

Does Orexin-B have human clinical trials?

The evidence review of Orexin-B is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Index by category›

Nootropic & Neuropeptides

Orexin-B

1 min read · Updated September 14, 2026 · 3 references

Curated by PeptideInfo Wikilast reviewed September 14, 2026how we verify

Explored forCognition, mood & sleep

Orexin-B, also called hypocretin-2, is a 28-amino-acid neuropeptide produced from the HCRT precursor.

Body & signals →

No receptor relationship mapped here yet. This does not mean the molecule has no biological effects.

Review pending

Contents3

Section 1 of 3What is it?

What is it?

Orexin-B, also called hypocretin-2, is a 28-amino-acid neuropeptide produced from the HCRT precursor. It has an amidated terminus. Orexin-A comes from the same precursor but is a different processed peptide, not another name for orexin-B. C01 (opens in a new tab)

Section 2 of 3What was studied?

What was studied?

The discovery study identified two peptides that activated related G protein-coupled receptors. Central administration increased food intake in rats. That animal experiment establishes neither a human appetite treatment nor a cognitive benefit from an intranasal product. C02 (opens in a new tab)

Section 3 of 3What does the result mean?

What does the result mean?

The OX2 receptor, encoded by HCRTR2, responds to both orexin peptides and participates in sleep–wake regulation. Activating this system and blocking it are opposite interventions. The orexin guide separates the endogenous signals from claims about treatments. C03 (opens in a new tab)

References3

References

1.
UniProt O43612 — human hypocretin precursor source
2.
Sakurai et al., 1998 — orexins and orexin receptors source
3.
UniProt O43614 — orexin receptor type 2 source

Frequently asked questions4

Frequently asked questions

What is Orexin-B?: Orexin-B, also called hypocretin-2, is a 28-amino-acid neuropeptide produced from the HCRT precursor.
Is Orexin-B approved as a medicine, and where?: The regulatory review of Orexin-B is incomplete. See the article's sources for product- and country-specific findings and remaining uncertainties. Review status means neither worldwide approval nor worldwide absence of approval.
What is Orexin-B studied for?: Orexin-B is most often discussed in the context of cognition, mood & sleep. Being studied for an area does not mean it is proven or approved for it.
Does Orexin-B have human clinical trials?: The evidence review of Orexin-B is in progress. The article's study appraisal identifies any human studies located and their limitations. An ongoing review does not itself mean that human studies are absent.

Educational disclaimer. This article summarizes published research for informational purposes and is not medical advice. The editorial review of Orexin-B is incomplete. Source-supported findings and remaining uncertainties are stated in the article; review status does not certify approval, safety or suitability for use. Consult a qualified healthcare professional before making health decisions.